Anaptysbio (ANAB) Net Income towards Common Stockholders Growth (3y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -9.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.83% |
| Dec 31, 2025 | 69.06% |
| Sep 30, 2025 | 36.66% |
| Jun 30, 2025 | -13.11% |
| Mar 31, 2025 | -7.79% |
| Dec 31, 2024 | 10.99% |
| Sep 30, 2024 | -69.89% |
| Jun 30, 2024 | -377.34% |
| Mar 31, 2024 | -34.23% |
| Dec 31, 2023 | 53.36% |
| Sep 30, 2023 | -16.22% |
| Jun 30, 2023 | -22.74% |
| Mar 31, 2023 | -69.05% |
| Dec 31, 2022 | -2.99% |
| Sep 30, 2022 | 4.10% |
| Jun 30, 2022 | -3.66% |
| Mar 31, 2022 | -12.47% |
| Dec 31, 2021 | -22.30% |
| Sep 30, 2021 | 25.12% |
| Jun 30, 2021 | 68.42% |
| Mar 31, 2021 | -6.39% |
| Dec 31, 2020 | 91.18% |
| Sep 30, 2020 | -37.76% |
| Jun 30, 2020 | -100.24% |
| Mar 31, 2020 | 7.07% |
| Dec 31, 2019 | -83.40% |
| Sep 30, 2019 | -203.05% |
| Jun 30, 2019 | -412.21% |
| Mar 31, 2019 | -160.15% |